Howard B Cottam
Immune Modulation, Inc., (IMI), USA
Dr. Cottam also holds a position as a Director of Medicinal Chemistry at the Moores Cancer Center at the University of California, San Diego. He previously held an executive position at ICN Pharmaceuticals, Inc., where he directed the synthesis of novel small molecular weight nucleosides with immunomodulatory, anti-tumor, anti-viral, and/or anti-parasitic properties. With more than thirty years experience managing the discovery and development of numerous medicinal products, Dr. Cottam has served as a consultant to Specialty Laboratories, Inc., DynaVax Technologies, Inc., Salmedix, Inc., ICN Pharmaceuticals, Inc., and MP Biomedicals, Inc. He is the author of over 80 publications in peer-reviewed medical and chemistry journals.
Parkinson’s Disease and Immunology
